Reactive Arthritis
Reactive arthritis (ReA), also known as Reiter's syndrome, is an inflammatory condition that typically occurs as a response to an infection in another part of the body. At our company, we specialize in the development services of innovative drugs and therapies for autoimmune diseases and inflammation, including the field of ReA.
Introduction to Reactive Arthritis
Reactive arthritis is a systemic inflammatory condition that primarily affects the joints, but can also involve other organs, such as the eyes, skin, and genitourinary system. It typically occurs after an infection, most commonly a gastrointestinal or genitourinary infection caused by bacteria like Chlamydia trachomatis, Salmonella, Shigella, or Campylobacter. The exact mechanisms that trigger the development of ReA are not fully understood, but it is believed to involve a combination of genetic predisposition, immune dysregulation, and microbial factors.
Fig.1 Consistent manifestations of reactive arthritis: arthritis and sacroiliitis. (Thomas K. N., et al., 2021)
Therapy Discovery and Development for Reactive Arthritis
Biological agents, including tumor necrosisfactor-alpha (TNF-α) inhibitors and other targeted therapies, have shown promising results in the therapeutic of refractory ReA. Elevated levels of TNF-α have been observed in chronic ReA, supporting the use of anti-TNF-α therapy. Our company is at the forefront of developing innovative biological agents, such as TNF-α antibodies, interleukin-6 receptor antibodies, and interleukin-17a monoclonal antibodies, that target specific pathways involved in the pathogenesis of ReA. These targeted therapies offer the potential for improved symptom management and disease control.
Our company is committed to developing diagnostics and innovative therapy options for ReA, targeting specific aspects of the disease's pathogenesis. To delve deeper into the wealth of knowledge surrounding our exceptional therapeutic development solutions, we kindly invite you to explore the following links.
Our Services
To better understand the pathogenesis of ReA and evaluate potential therapeutic interventions, we offer the development of robust animal models and in vitro models. Our team of experienced researchers utilizes cutting-edge techniques to create animal models that closely mimic the disease characteristics of ReA. Additionally, our in vitro models allow for the investigation of cellular and molecular mechanisms involved in ReA, enabling the screening and validation of potential drug candidates.
Yersinia Enterocolitica Induced Models
At our company, we have focused on the development of animal models specifically induced by Yersinia enterocolitica infection. Several strains of rats have been tested to evaluate their susceptibility to developing arthritis upon exposure to this bacterial pathogen.
Developing co-culture systems that incorporate multiple cell types involved in reactive arthritis, such as synovial fibroblasts, macrophages, and T cells, allows for a more comprehensive understanding of the disease pathogenesis and evaluation of therapies.
Organoids, three-dimensional miniaturized organ-like structures derived from stem cells, have revolutionized disease modeling. Our company recognizes the potential of organoid models and offers specialized services, including synovial organoids and gut-synovium axis models.
References
- Thomas Koshy Nithin, Anamika Kumari Anuja, and Latika Gupta. "Clinical profile of adults and children with reactive arthritis in India–A cohort study." Indian Journal of Rheumatology 15.4 (2020): 304-309.
- Bentaleb Ibtissam, et al. "Reactive arthritis: update." Current clinical microbiology reports 7 (2020): 124-132.